Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Roivant Sciences Ltd. (ROIV)

As of 2026-11-17 · 12/15 boxes filled from SEC filings and market data

Report price $38.71 (close 2026-11-17); latest close $38.66 (2026-11-20), -0.1% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -42% · upside +0%

At $38.71, a $28.05B market cap and $23.84B enterprise value pay 580.31x EV/Sales and 682.73x P/S on TTM revenue of $41.1M, while EBIT is -$558.0M. The market is pricing a great deal of future success into a company whose TTM revenue base is tiny and whose losses are large, and the balance sheet funds the burn rather than proving earning power. The label is PASS. The downside is -42.3% to $22.34, set by 0.0% sales at a compressed EV/Sales of 291.65x (today 580.31x). There is no base case: the 3.53x peer EV/Sales median comes from profitable peers with at most 0.08 business similarity to ROIV, whose TTM revenue is $41.1M and EBITDA -$555.4M, while the $22.34 level is still 291.65x EV/Sales, 45x ARQT's 6.47x, so no comparable peer multiple sets a valuation base. The upside is 0.0% at $38.71, the analyst's own upside, with no earnings change given to price it. With no base and no upside return, the call follows.

Key numbers

  • Share price: $38.66
  • Market cap: $28.01B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $41.1M
  • FCF yield: -0.1%
  • Price / book: 6.97x
  • Earnings-quality flags (TTM): Investment gains/losses $92.6M (27% of net income)
  • Revenue growth (latest fiscal year): -71.6%

The 15 boxes

  1. ✓ 1. Long-form business notes

    Roivant is a biopharma Vant-holding model: it develops or in-licenses drugs through subsidiaries, shares economics with minority holders, and layers licensing royalties and milestones on top, but the annual-report excerpts do not give segment revenue or unit economics. The cycle is extreme: FY2026 revenue was $8.3M versus $32.7M in FY2024, operating income was -$515.1M versus $4.50B in FY2024, and TTM to Sep 2026 revenue was $41.1M with operating income of -$558.0M. Operating cash flow was negative in every fiscal year shown, though TTM was -$36.4M versus -$750.3M in FY2026. The newest 10-K shows brepocitinib near launch, batoclimab discontinued, Dermavant sold to Organon in October 2024, and a $2.25B Moderna settlement that is separate from operating earnings.

  2. ✓ 2. Competitive advantage

    No durable advantage is visible in the filings: Roivant is early-commercial rather than purely clinical-stage, with LISRAYA (brepocitinib) approved in August 2026 and $31.0 million of product revenue in its first five weeks (Q2 FY2026), while naming FcRn blockers (VYVGART, VYVGART Hytrulo, IMAAVY, RYSTIGGO) and prostacyclin mimetics (Tyvaso, Yutrepia) as competitors owned by companies with substantially greater financial, technical and human resources. The core IMVT-1402/batoclimab rights sit inside a terminable HanAll licence, and the April 2026 batoclimab Phase 3 TED failure removed that program across all indications. The record shows why no operating moat exists: FY2026 revenue of $8.3M against operating income of -$515.1M, and the one positive operating year (FY2024, +$4.50B on $32.7M revenue) has not recurred; what funds the company is balance-sheet cash (~$4.3B at 2026-03-31), not returns on capital.

  3. ✓ 3. 10-Q takeaways

    The September 2026 quarter is the first product-revenue quarter: LISRAYA generated $31.0 million in its first five weeks, total revenue was $35.1 million versus $1.6 million a year earlier, but the company still had a $268.0 million operating loss and a $191.6 million net loss attributable to Roivant. Cash was $4.2 billion at September 30, 2026, and the quarter included $72.5 million of buybacks; the reported net loss included a $60.3 million unrealized investment gain and $15.8 million of discontinued-operations income, so it is not an operating profit. The 10-Q says no material risk-factor changes in the quarter, and neither the 10-Q nor the same-quarter release gives numeric revenue or EPS guidance, only event timing and cash runway into profitability.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans